In the last trading session, 1.22 million Atyr Pharma Inc (NASDAQ:ATYR) shares changed hands as the company’s beta touched 0.74. With the company’s per share price at $3.44 changed hands at $0.17 or 5.20% during last session, the market valuation stood at $306.17M. ATYR’s last price was a discount, traded about -35.47% off its 52-week high of $4.66. The share price had its 52-week low at $1.42, which suggests the last value was 58.72% up since then.

Atyr Pharma Inc (NASDAQ:ATYR) trade information

Instantly ATYR was in green as seen at the end of in last trading. With action 6.17%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -4.97%, with the 5-day performance at 6.17% in the green. However, in the 30-day time frame, Atyr Pharma Inc (NASDAQ:ATYR) is 10.97% up.

Atyr Pharma Inc (ATYR) estimates and forecasts

Year-over-year growth is forecast to reach 751.06% up from the last financial year.

10 analysts are of the opinion that Atyr Pharma Inc’s revenue for the current quarter will be 1.2M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 34.28%. The 2025 estimates are for Atyr Pharma Inc earnings to increase by 23.15%.

Atyr Pharma Inc (NASDAQ:ATYR)’s Major holders

Among Mutual Funds, the top two as of Jan 31, 2025 were Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund and Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund. With 7.85 shares estimated at $27.0 million under it, the former controlled 8.82% of total outstanding shares. On the other hand, Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund held about 7.44% of the shares, roughly 6.62 shares worth around $22.77 million.